KAAPA, a Finnish biotechnology startup, has impressed major global nutritional supplement producers. The demand for the firm’s wholesale product has increased significantly over time. As a result, KAAPA Biotech has decided to enter the Serie A investment stage. This move is expected to scale up its production capacity to match the high global demand for its medicinal mushroom extracts.
Over the past few years, the medicinal mushroom market has undergone rapid growth. However, until now, the market has lacked innovative, high-quality, transparent, and sustainable approaches. The rising demand for premium quality organic medical mushroom ingredients has inspired KAAPA Biotech to develop the Nordic Mushrooms Product line that includes Finnish grown organic Chaga, Reishi, Shiitake, Lion’s Mane, and Maitake.
According to Eric Puro, CEO of KAAPA Biotech, “As pioneers within the nutritional supplement industry, KAAPA implements the industry’s megatrends of sustainability, transparency, and traceability. Sustainability is an integral part of KAAPA Biotech’s business model. We have developed a fully transparent supply chain, focusing on organic Finnish grown ingredients, controlled from spore to shipment.” The biotech company has also done extensive research on the compounds of interest that are found on medicinal mushrooms, such as beta-glucans. The high-tech production techniques applied by KAAPA ensure a safer and effective means of producing the purest and most potent mushroom extracts in the market.
“We have developed industry-leading ultrasonic-assisted extraction technology which is optimized for bioavailability of the compounds of interest in our mushroom extracts,” Said Eric Puro. “We are constantly reaching, developing, and commercializing new mushroom-based product innovations through the latest scientific methods available,” he added.
The Series A investment will be applied to scale up the manufacturing capacity of the Nordic Mushrooms product line. The organization has acquired unique growing methods for the mushrooms used to produce the Nordic Mushrooms extracts. The mushrooms supply amount will be increased to match the demand by upgrading the indoor growing facilities. Furthermore, the production equipment will be scaled up to produce significant batches of the product line.
Eric Puro, the CEO of KAAPA Biotech, also explained that it would be possible to accommodate all the new large customers by raising the capital. “The feedback from the industry tells us that our product line is what the market has been awaiting. We are now looking for one of the three strategic partners to raise 3 million Euros to support our growth strategy and enter into the industrial manufacturing stage,” he added.
